Development of new therapeutic strategies for Parkinson's disease based on replacement of L-DOPA using rAAV vectors

被引：0
|
作者：
Kirik, D. [1 ]
机构：
[1] Lund Univ, Dept Expt Med Sci, Sect Neurosci, CNS Dis Modeling Unit, Lund, Sweden
来源：
CELL TRANSPLANTATION | 2006年 / 15卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
引用
收藏
页码：561 / 561
页数：1
相关论文
共 50 条
  • [31] L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning
    Chagraoui, Abdeslam
    Boulain, Marie
    Juvin, Laurent
    Anouar, Youssef
    Barriere, Gregory
    De Deurwaerdere, Philippe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [32] L-dopa plasma levels and executive functions in Parkinson's disease
    Albani, G.
    Cattaldo, S.
    Mori, I.
    Pignatti, R.
    Pradotto, L.
    Mauro, A.
    MOVEMENT DISORDERS, 2009, 24 : S289 - S289
  • [33] The Effect of L-dopa on Postural Stability in Parkinson's Disease Patients
    Wilczynski, Jacek
    Habik, Natalia
    APPLIED SCIENCES-BASEL, 2019, 9 (03):
  • [34] Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients
    O. Bartošová
    C. Bonnet
    O. Ulmanová
    M. Šíma
    F. Perlík
    E. Růžička
    O. Slanař
    Journal of Neural Transmission, 2018, 125 : 699 - 703
  • [35] L-dopa therapy for Parkinson's disease: Past, present, and future
    Nagatsu, Toshiharu
    Sawada, Makoto
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S3 - S8
  • [36] Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa
    A. W. Michell
    Z. Xu
    D. Fritz
    S. J. G. Lewis
    T. Foltynie
    C. H. Williams-Gray
    T. W. Robbins
    R. H. S. Carpenter
    R. A. Barker
    Experimental Brain Research, 2006, 174 : 7 - 18
  • [37] Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients
    Bartosova, O.
    Bonnet, C.
    Ulmanova, O.
    Sima, M.
    Perlik, F.
    Ruzicka, E.
    Slanar, O.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (04) : 699 - 703
  • [38] Disease progression and increased L-dopa efficacy with time in Parkinson's disease
    Holford, NHG
    Chan, PLS
    Lee, YY
    Nutt, JG
    MOVEMENT DISORDERS, 2002, 17 : S112 - S112
  • [39] Molecular mechanism of L-Dopa induced dyskinesia in Parkinson's disease
    Subhani, F. U. -H.
    Subhani, A.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S118 - S119
  • [40] Arguments favoring early treatment of Parkinson's disease with L-Dopa
    Broussolle, E
    REVUE NEUROLOGIQUE, 1999, 155 (01) : 27 - 33
12345